Study of PIT565 in relapsed and/or refractory B-cell malignancies
CPIT565A12101
Phase 1 other active
Quick answer
Study of PIT565 in relapsed and/or refractory B-cell malignancies for Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
- Phase
- Phase 1
- Modality
- other
- Status
- active